Phase I clinical trial of donor t-helper type 2 cells after immunoablative, reduced intensity allogeneic PBSC transplant

Cytotherapy

Volumn 4, Issue 5, 2002, Pages 429-430

  Fowler, Daniel ^a   Hou, J ^a   Foley, J ^a   Hakim, F ^a   Odom, J ^a   Castro, K ^a   Carter, C ^b   Read, E ^b   Gea Banacloche, J ^a   Kasten Sportes, C ^a   Kwak, L ^a   Wilson, W ^a   Levine, B ^c   June, C ^c   Gress, R ^a   Bishop, M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL INSTITUTES OF HEALTH   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD4 ANTIGEN; CYCLOPHOSPHAMIDE; CYTOKINE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; GRANULOCYTE COLONY STIMULATING FACTOR; PREDNISONE; VINCRISTINE;

ALLOTRANSPLANTATION; ANTIGEN PURIFICATION; ANTINEOPLASTIC ACTIVITY; CANCER COMBINATION CHEMOTHERAPY; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DONOR; DRUG SAFETY; FEASIBILITY STUDY; FOLLOW UP; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INCIDENCE; NONHODGKIN LYMPHOMA; PHASE 1 CLINICAL TRIAL; STEM CELL MOBILIZATION; TH2 CELL; ARTICLE; CD4+ T LYMPHOCYTE; IMMUNOLOGY; METHODOLOGY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; STEM CELL TRANSPLANTATION; TIME; TRANSPLANTATION;

CD4-POSITIVE T-LYMPHOCYTES; GRAFT VS HOST DISEASE; HUMANS; LYMPHOMA, NON-HODGKIN; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; STEM CELL TRANSPLANTATION; TH2 CELLS; TIME FACTORS;

EID: 18744415962     PISSN: 14653249     EISSN: None     Source Type: Journal    
DOI: 10.1080/146532402320776053     Document Type: Conference Paper

References (12)

1. Hill GR, Ferrara JL. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: Rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 2000;95:2754-9.
2. Slavin S, Nagler, A, Naparstek E et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and non-malignant hematologic diseases. Blood 1998;91:756-63.
3. McSweeney PA, Niederwieser D, Shizuru JA et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: Replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001;97:3390-3400.
4. Spitzer TR, McAfee S, Sackstein R et al. Intentional induction of mixed chimerism and achievement of antitumor responses after nonmyeloablative conditioning therapy and HLA-matched donor bone marrow transplantation for refractory hematologic malignancies. Biol Blood Marrow Transplant 2000;6:309-20.
5. Childs R, Clave E, Contentin N et al. Engraftment kinetics after nonmyeloablative allogeneic peripheral blood stem cell transplantation: Full donor T-cell chimerism precedes alloimmune responses. Blood 1999;94:3234-41.
6. Khouri IF, Saliba RM, Giralt SA et al. Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: Low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality. Blood 2001;98:3595-9.
7. Petrus MJ, Williams JF, Eckhaus MA et al. An immunoablative regimen of fludarabine and cyclophosphamide prevents fully MHC-mismatched murine marrow graft rejection independent of GVHD. Biol Blood Marrow Transplant 2000;6:182-9.
8. + lymphoid engraftment. J Immunol 1993;152:1004-13.
9. + donor T cells fail to induce experimental acute graft-versus-host disease. J Immunol 1995;155:585-93.
10. Gutierrez M, Chabner BA, Pearson D et al. Role of a doxorubicin-containing regimen in relapsed and resistant lymphomas: An 8-year follow-up study of EPOCH. J Clin Oncol 2000;18:3633-42.
11. + T cells in the absence of exogenous feeder cells. J Immunol 1997;159:5921-30.
12. Deeg HJ, Flowers ME, Leisenring W et al. Cyclosporine (CSP) or CSP plus methylprednisolone for graft-versus-host disease prophylaxis in patients with high-risk lymphohemopoietic malignancies: Long-term follow-up of a randomized trial. Blood 2000;96:1194-5.